Abstract
Background: The Oncotype DX breast cancer assay provides a marker for risk of distant recurrence and patients in the intermediate risk group were often advised chemotherapy. The TAILORx study showed, in patients over 50 with a risk score of less than 25 and in patients younger than 50, with a risk score less than 20, that chemotherapy could be spared.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
